title: The role of mirabegron in overactive bladder: a systematic review and meta-analysis.
abstract: OBJECTIVE
  To present a systematic review assessing the efficacy and safety of mirabegron for overactive bladder (OAB).
  
  
  METHODS
  A literature search was performed using the Cochrane Library, MEDLINE, EMBASE and Science Citation Index Expanded. The literature reviewed included meta-analyses, randomized and nonrandomized prospective studies. We utilized mean difference (MD) to measure the mean number of incontinence episodes and the mean number of micturitions, and OAB questionnaire (OAB-q) and odds ratio (OR) to measure adverse events rates. We used the Cochrane Collaboration's Review Manager 5.1 software for statistical analysis.
  
  
  RESULTS
  We identiﬁed six publications that strictly met our eligibility criteria. Meta-analysis of extractable data showed that mirabegron was more effective than placebo in treating OAB despite different drug dosages in the efficacy end points: mean number of incontinence episodes per 24 h (MD -0.54; 95% CI -0.63, -0.45; p = 0.001), mean number of micturitions per 24 h (MD -0.55; 95% CI -0.63, -0.47; p = 0.001), OAB-q (MD -4.49; 95% CI -6.27, -2.71; p = 0.001) and adverse events (OR 0.99; 95% CI 0.83, 1.19; p = 0.92). When compared to tolterodine, mirabegron was more effective in terms of mean number of incontinence episodes per 24 h (MD -0.25; 95% CI -0.43, -0.06; p = 0.009). However, there were no differences between mirabegron and tolterodine in mean number of micturitions per 24 h (MD -0.17; 95% CI -0.35, 0.01; p = 0.07) and OAB-q (MD -1.09; 95% CI -2.51, 0.33; p = 0.13). Mirabegron also had a lower adverse reaction rate (OR 0.9; 95% CI 0.8, 1.0; p = 0.04).
  
  
  CONCLUSIONS
  In this diverse population, mirabegron was an effective and safe pharmacologic therapy for OAB.
authors.affiliation: Department of Urology, West China Hospital, Sichuan University, Chengdu, China.
authors.forename: Tao
authors.initials: T
authors.lastname: Wu
authors.forename: Xi
authors.initials: X
authors.lastname: Duan
authors.forename: Chen-Xi
authors.initials: CX
authors.lastname: Cao
authors.forename: Chuan-Du
authors.initials: CD
authors.lastname: Peng
authors.forename: Si-Yuan
authors.initials: SY
authors.lastname: Bu
authors.forename: Kun-Jie
authors.initials: KJ
authors.lastname: Wang
mesh_terms: D000083:Acetanilides / Q000627:therapeutic use*; D001559:Benzhydryl Compounds / Q000627:therapeutic use; D003408:Cresols / Q000627:therapeutic use; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D016017:Odds Ratio; D010665:Phenylpropanolamine / Q000627:therapeutic use; D011446:Prospective Studies; D012107:Research Design; D012984:Software; D011795:Surveys and Questionnaires; D013844:Thiazoles / Q000627:therapeutic use*; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000188:drug therapy; D014554:Urination / Q000187:drug effects; D064804:Urological Agents / Q000627:therapeutic use
chemical_list: D000083:Acetanilides; D001559:Benzhydryl Compounds; D003408:Cresols; D018727:Muscarinic Antagonists; D013844:Thiazoles; D064804:Urological Agents; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; C520025:mirabegron